Going Concern (removed) — Prior-year auditor going-concern opinion no longer disclosed in current filing despite accumulated deficit growing from $87M to $110M; removal reflects auditor determination rather than fundamental liquidity improvement.

NYSE: MAIA MAIA Biotechnology, Inc. 10-K

MAIA initiates Phase 3 trial, secures FDA Fast Track, raises $33M; crypto strategy announced then shelved

Filed March 23, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 21, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade MAIA commission-free

Open an account, get a free stock.

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 4, 2026 5:29 AM